Shorter Disease Duration Predicts Earlier Complete Skin Clearance in Biologic-naïve Psoriasis Treated with Biologics
DOI:
https://doi.org/10.2340/actadv.v106.adv-2026-0697Keywords:
psoriasis, biologics, disease duration, complete skin clearance, real-world studyAbstract
The association between psoriasis disease duration and complete skin clearance after biologic initiation remains uncertain. This single-centre retrospective study included 218 biologic-naïve patients who initiated biologic therapy between 2010 and 2024. Disease duration was defined as the interval from symptom onset to biologic initiation and categorized as ≤2 years or >2 years. Absolute Psoriasis Area and Severity Index (PASI) 0 was assessed at 3 months, 6 months, 1 year and 2 years using an as-observed approach. Twenty-nine patients (13.3%) had disease duration ≤2 years. At 3 months, absolute PASI 0 was achieved in 6/29 (20.7%) patients with shorter disease duration and 14/189 (7.4%) with longer disease duration (p=0.033). No significant differences were detected at subsequent assessments. In an exploratory multivariable Cox model including baseline PASI, shorter disease duration was associated with early PASI 0 achievement (hazard ratio 4.75; 95% confidence interval 1.57–14.40). Sparse early events and incomplete covariate data limit interpretation. Shorter disease duration was associated with earlier complete skin clearance; larger studies are needed to establish whether this association is independent of treatment selection and other confounders.
Downloads
References
Lubrano E, Scriffignano S, Perrotta FM. Psoriatic Arthritis, Psoriatic Disease, or Psoriatic Syndrome? J Rheumatol 2019; 46: 1428–1430.
Kamata M, Tada Y. Efficacy and Safety of Biologics for Psoriasis and Psoriatic Arthritis and Their Impact on Comorbidities: A Literature Review. Int J Mol Sci 2020; 21: 1690.
Alinaghi F, Calov M, Kristensen LE, Gladman DD, Coates LC, Jullien D, et al. Prevalence of psoriatic arthritis in patients with psoriasis: A systematic review and meta-analysis of observational and clinical studies. J Am Acad Dermatol 2019; 80: 251–265.
Koehm M, Behrens F. Association between biological immunotherapy for psoriasis and time to incident inflammatory arthritis: limitations and opportunities. RMD Open 2023; 9: 9.
Acosta Felquer ML, LoGiudice L, Galimberti ML, Rosa J, Mazzuoccolo L, Soriano ER. Treating the skin with biologics in patients with psoriasis decreases the incidence of psoriatic arthritis. Ann Rheum Dis 2022; 81: 74–79.
Gisondi P, Bellinato F, Targher G, Idolazzi L, Girolomoni G. Biological disease-modifying antirheumatic drugs may mitigate the risk of psoriatic arthritis in patients with chronic plaque psoriasis. Ann Rheum Dis 2022; 81: 68–73.
Rosenthal YS, Schwartz N, Sagy I, Pavlovsky L. Incidence of Psoriatic Arthritis Among Patients Receiving Biologic Treatments for Psoriasis: A Nested Case-Control Study. Arthritis Rheumatol 2022; 74: 237–243.
Floris A, Mugheddu C, Sichi L, Anedda J, Frau A, Sorgia J, et al. Treatment of psoriasis with different classes of biologics reduces the likelihood of peripheral and axial psoriatic arthritis development. Rheumatology (Oxford) 2025; 64: 1131–1137.
Dalgard FJ, Gieler U, Tomas-Aragones L, Lien L, Poot F, Jemec GBE, et al. The psychological burden of skin diseases: a cross-sectional multicenter study among dermatological out-patients in 13 European countries. J Invest Dermatol 2015; 135: 984–991.
Garshick MS, Ward NL, Krueger JG, Berger JS. Cardiovascular Risk in Patients With Psoriasis. J Am Coll Cardiol 2021; 77: 1670–1680.
Prodanovich S, Kirsner RS, Kravetz JD, Ma F, Martinez L, Federman DG. Association of psoriasis with coronary artery, cerebrovascular, and peripheral vascular diseases and mortality. Arch Dermatol 2009; 145: 700–703.
Abuabara K, Azfar RS, Shin DB, Neimann AL, Troxel AB, Gelfand JM. Cause-specific mortality in patients with severe psoriasis: a population-based cohort study in the U.K. Br J Dermatol 2010; 163: 586–592.
Kimball AB, Gieler U, Linder D, Sampogna F, Warren RB, Augustin M. Psoriasis: is the impairment to a patient’s life cumulative? J Eur Acad Dermatol Venereol 2010; 24: 989–1004.
Okuse M, Soekawa M, Itakura A, Kawamura T, Mburu S, Frade S, et al. Perspectives of Japanese patients on psoriatic disease burden: Results from “Psoriasis and Beyond,” the Global Psoriatic Disease Survey. J Dermatol 2024; 51: 1298–1309.
Augustin M, Gottlieb AB, Lebwohl M, Pinter A, Warren RB, Puig L, et al. Complete Skin Clearance is Associated with the Greatest Benefits to Health-Related Quality of Life and Perceived Symptoms for Patients with Psoriasis. Dermatol Ther (Heidelb) 2024; 14: 2841–2857.
Korman NJ, Malatestinic W, Goldblum OM, Murage MJ, Renda L, Lin CY, et al. Assessment of the benefit of achieving complete versus almost complete skin clearance in psoriasis: a patient’s perspective. J Dermatolog Treat 2022; 33: 733–739.
Schäkel K, Reich K, Asadullah K, Pinter A, Jullien D, Weisenseel P, et al. Early disease intervention with guselkumab in psoriasis leads to a higher rate of stable complete skin clearance ('clinical super response’): Week 28 results from the ongoing phase IIIb randomized, double-blind, parallel-group, GUIDE study. J Eur Acad Dermatol Venereol 2023; 37: 2016–2027.
Gargiulo L, Ibba L, Malagoli P, Amoruso F, Argenziano G, Balato A, et al. A risankizumab super responder profile identified by long-term real-life observation-IL PSO (ITALIAN LANDSCAPE PSORIASIS). J Eur Acad Dermatol Venereol 2024; 38: e113–e116.
Eyerich K, Asadullah K, Pinter A, Weisenseel P, Reich K, Paul C, et al. Noninferiority of 16-Week vs 8-Week Guselkumab Dosing in Super Responders for Maintaining Control of Psoriasis: The GUIDE Randomized Clinical Trial. JAMA Dermatol 2024; 160: 953–963.
Kamata M, Tada Y. Crosstalk: keratinocytes and immune cells in psoriasis. Front Immunol 2023; 14: 1286344.
Blauvelt A, Papp K, Gottlieb A, Jarell A, Reich K, Maari C, et al. A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial. Br J Dermatol 2020; 182: 1348–1358.
Blauvelt A, Leonardi C, Elewski B, Crowley JJ, Guenther LC, Gooderham M, et al. A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 24-week efficacy and safety results from a randomized, double-blinded trial. Br J Dermatol 2021; 184: 1047–1058.
Van Muijen ME, Thomas SE, Groenewoud HMM, Otero ME, Ossenkoppele PM, Njoo MD, et al. Direct Comparison of Real-world Effectiveness of Biologics for Psoriasis using Absolute and Relative Psoriasis Area and Severity Index Scores in a Prospective Multicentre Cohort. Acta Derm Venereol 2022; 102: adv00712.
Additional Files
Published
How to Cite
License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
